

FORM PTO-1594  
(Rev. 03/01)  
OMB No. 0651-0027 (exp. 5/31/2002)

12-11-2001

U.S. DEPARTMENT OF COMMERCE  
U.S. Patent and Trademark Office



101912096

To the Honorable Commissioner of Patents and Trademarks, U.S. Department of Commerce, Washington, D.C. 20231  
original documents or copy thereof.

*Handwritten:* m 12/11/01

1. Name of conveying party(ies):

MedImmune Oncology, Inc.

- Individual(s)
- General Partnership
- Corporation-State Delaware
- Other \_\_\_\_\_

Additional name(s) of conveying party(ies) attached?  Yes  No

2. Name and address of receiving party(ies):

Name: MGI Pharma, Inc.

Street Address:  
5775 West Old Shakopce Road  
Suite 100  
Bloomington, MN 55437

3. Nature of conveyance:

- Assignment
- Security Agreement
- Other \_\_\_\_\_

Execution Date: October 26, 2000

- Individual(s)
- General Partnership
- Corporation-State Minnesota
- Other \_\_\_\_\_

If assignee is not domiciled in the United States, a domestic representative designation is attached:  Yes  No  
(Designations must be a separate document from assignment)  
Additional name(s) & address(es) attached?  Yes  No

4. Application number(s) or registration number(s):

A. Trademark Application No.(s)

B. Trademark registration No.(s)

1,540,083

Additional numbers attached?  Yes  No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Carolyn M. Sandberg

Internal Address: 300.239US1  
Schwegman, Lundberg, Woessner & Kluth, P.A.  
P.O. Box 2938  
Minneapolis, MN 55402-0938

6. Total number of applications and registrations involved: 1

7. Total fee (37 CFR 3.41): \$ 40.00

- Enclosed
- Authorized to be charged to deposit account

*Handwritten:* 40E

8. Please charge any additional fees or credit any overpayments to our Deposit account number: 19-0743

**DO NOT USE THIS SPACE**

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Carolyn M. Sandberg  
Name of Person Signing

*Handwritten Signature: Carolyn M. Sandberg*  
Signature

December 11, 2001  
Date

Total number of pages including cover sheet: 4

**Do not detach this portion**

Mail documents to be recorded with required cover sheet information to:

Commissioner of Patents and Trademarks,  
Box Assignments  
Washington, D.C. 20231

**EXHIBIT F****FORM OF TRADEMARK ASSIGNMENT**

This Assignment (the "Assignment") is made by and between MedImmune Oncology, Inc., a Delaware corporation ("MedImmune") and MGI Pharma, Inc., a Minnesota corporation ("MGI").

WHEREAS, the parties have entered into that certain Asset Purchase Agreement dated as of October 26, 2000 (the "Asset Purchase Agreement") pursuant to which MedImmune is selling, and MGI is purchasing certain Purchased Assets, including Trademarks (as both terms are defined in such Asset Purchase Agreement);

WHEREAS, MGI desires to acquire the Trademarks and any applications and registrations therefor, including the registrations identified on Exhibit A.

NOW, THEREFORE, for good and valuable consideration received by MedImmune from MGI, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

1. **Assignment of Trademarks.** MedImmune hereby sells, assigns, transfers and conveys to MGI all rights, title and interest in and to the Trademarks, and any applications and registrations therefor, including the applications and registrations identified on the attached Exhibit A, together with that part of the good will of the business associated with the use of and symbolized by the Trademarks, to be held and enjoyed by MGI as fully and entirely as said interest could have been held and enjoyed by MedImmune if this sale, assignment and transfer had not been made.
2. **Assignment of Causes of Action.** MedImmune further sells, assigns, transfers and conveys to MGI the entire right, title and interest in and to any and all causes of action and rights of recovery for past infringement of the Trademarks.
3. **Cooperation.** To the extent provided in the Asset Purchase Agreement, MedImmune hereby covenants and agrees to cooperate with MGI so that MGI may enjoy to the fullest extent the rights, title and interest herein conveyed. Such cooperation shall include prompt execution of all papers prepared at the expense of MGI which are deemed by MGI in its reasonable discretion necessary or desirable to perfect in it the rights, title and interest herein conveyed.
4. **Survival.** The terms, covenants and provisions of this Assignment shall inure to the benefit of MGI, its successors, assigns, and/or legal representatives, and shall be binding upon MedImmune, its successors, assigns and/or other legal representatives.

IN WITNESS WHEREOF, MedImmune has executed this Assignment and such Assignment is effective as of the date indicated below.

MEDIMMUNE ONCOLOGY, INC.

Date: October 26, 2000


By: 

EXHIBIT A  
TRADEMARKS

Hexalen	
* U.S. Registration No.:	1540083
Date of Registration:	May 23, 1989
Hexalen	
Australia Registration No.:	628810
Date of Registration:	May 3, 1994
Hexalen	
Benelux Registration No.:	540740
Date of Registration:	October 8, 1993
Hexalen	
Bolivia Registration No.:	55822
Date of Registration	February 24, 1994
Hexalen	
Brazil Registration No.:	816824681
Date of Registration	November 30, 1993
Hexalen	
Canada Registration No.:	439,429
Date of Registration	February 17, 1995
Hexalen	
Chile Registration No.:	433.214
Date of Registration	October 26, 1994
Hexalen	
China Registration No.:	757823
Date of Registration	July 28, 1995
Hexalen	
Colombia Registration No.:	187,427
Date of Registration	March 26, 1996
Hexalen	
Costa Rica Registration No.:	82,066
Date of Registration	January 26, 1993
Hexalen	
Denmark Registration No.:	03666/1997